P2Y<sub>14</sub> receptor | P2Y receptors | IUPHAR/BPS Guide to PHARMACOLOGY

P2Y14 receptor

Target id: 330

Nomenclature: P2Y14 receptor

Family: P2Y receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     P2Y14 receptor has curated GtoImmuPdb data

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 338 3q24-q25.1 P2RY14 purinergic receptor P2Y14 8,31
Mouse 7 338 3 29.5 cM P2ry14 purinergic receptor P2Y, G-protein coupled, 14 11
Rat 7 305 2q31 P2ry14 purinergic receptor P2Y14 11
Previous and Unofficial Names
G protein coupled receptor for UDP-glucose | G protein-coupled receptor 105 | GPR105 | P2Y purinoceptor 14 | G-protein coupled receptor 105 | purinergic receptor P2Y
Database Links
Specialist databases
GPCRDB p2y14_human (Hs), p2y14_mouse (Mm), p2y14_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
UDP-glucose
Potency order of endogenous ligands (Human)
uridine diphosphate  [6]

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
α.β-methylene-2-thio-UDP Hs Full agonist 9.0 pEC50 9
pEC50 9.0 (EC50 9.2x10-10 M) [9]
MRS4183 Hs Agonist 9.0 pEC50 22
pEC50 9.0 (EC50 9.6x10-10 M) [22]
Description: Measuring inhibition of forskolin-stimulated cAMP formation in CHO cells expressing the human P2Y14 receptor
MRS2905 Hs Agonist 9.0 pEC50 21
pEC50 9.0 (EC50 9.2x10-10 M) [21]
2-thio-UDP Hs Full agonist 8.7 pEC50 9
pEC50 8.7 (EC50 1.92x10-9 M) [9]
UDP-glucose Mm Full agonist 7.7 pEC50 11
pEC50 7.7 [11]
UDP-galactose Mm Full agonist 7.6 pEC50 11
pEC50 7.6 [11]
UDP-glucose Rn Full agonist 7.6 pEC50 11
pEC50 7.6 [11]
UDP-glucuronic acid Hs Full agonist 7.2 pEC50 12
pEC50 7.2 [12]
UDP-glucuronic acid Mm Full agonist 7.2 pEC50 11
pEC50 7.2 [11]
MRS2802 Hs Agonist 7.2 pEC50 9
pEC50 7.2 (EC50 6.3x10-8 M) [9]
uridine diphosphate Hs Full agonist 7.1 pEC50 6
pEC50 7.1 (EC50 7.4x10-8 M) [6]
UDP-galactose Rn Full agonist 7.1 pEC50 11
pEC50 7.1 [11]
UDP N-acetyl-glucosamine Mm Full agonist 7.0 pEC50 11
pEC50 7.0 [11]
UDP-galactose Hs Full agonist 7.0 pEC50 12
pEC50 7.0 [12]
UDP-glucuronic acid Rn Full agonist 7.0 pEC50 11
pEC50 7.0 [11]
MRS2690 Hs Agonist 6.6 – 7.3 pEC50 16,24
pEC50 6.6 – 7.3 (EC50 2.29x10-7 – 4.9x10-8 M) [16,24]
UDP N-acetyl-glucosamine Rn Full agonist 6.8 pEC50 11
pEC50 6.8 [11]
UDP N-acetyl-glucosamine Hs Full agonist 6.0 pEC50 12
pEC50 6.0 [12]
UDP-glucose Hs Full agonist 7.1 pIC50 12
pIC50 7.1 [12]
uridine diphosphate Rn Full agonist 6.5 pIC50 13
pIC50 6.5 [13]
View species-specific agonist tables
Agonist Comments
UDP-galactose, UDP glucuronic acid and UDP N-acethyl-glucosamine have also been reported to act as partial agonists [34]. Several analogues of UDP-glucose modified on nucleobase, ribose and glucose moieties have been synthesyzed and pharmacologically characterized in association with modeling studies [24]. Molecular dynamics of P2Y14 has allowed analysis of the putative receptor binding site to UDP-glucose and derivatives [20]. Covalent conjugation of polyamidoamine dendrimers to UDP-glucose enhances pharmacological activity of the agonist [10]. Further compounds with agonist activity have been synthesized and not included in this table [9].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
PPTN Hs Antagonist 10.1 pKi 2
pKi 10.1 (KB 4.34x10-10 M) [2]
MRS4174 Hs Antagonist 10.1 pKi 23
pKi 10.1 (Ki 8x10-11 M) [23]
MRS4458 Hs Antagonist 6.8 pIC50 38
pIC50 6.8 (IC50 1.69x10-7 M) [38]
MRS4478 Hs Antagonist 6.6 pIC50 38
pIC50 6.6 (IC50 2.69x10-7 M) [38]
Antagonist Comments
UDP was previously described to be a competitive antagonist in cells transfected with the human receptor [13]. This statement has been revised by further studies from the same group [6]. SAR studies identified compounds acting as antagonists at P2Y14 with good pharmacokynetic properties [17-18,32]. A non-nucleotidic ligand has been demonstrated to be active on P2Y14 [19].
Immunopharmacology Comments
In reponse to activation by uridine nucleotides (which can be released by stressed ot damaged tissues and organs) the P2Y14 receptor (P2Y14R) activates pro-inflammatory activity in part by increasing neutrophil motility [2,35], and this boosts the innate and adaptive immune responses [1,5,7]. In order to examine the potential anti-inflammatory effects arising from P2Y14R blockade, selective antagonist molecules are being developed [38].
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  33
Secondary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Phospholipase C stimulation
Comments: 

P2Y14 coupled to Gαi, can activate PLCβ via beta/gamma subunits. It has been demonstrated that in endothelial cells calcium influx are mediated by β/γ subunits of Gα0 but not to Gαi [311,154].

Primary glial cells have been reported to respond to UDP-glucose with increases of intracellular calcium concentrations highlighting a role for this receptor in glial cells [4,14].
References:  4,29
Tissue Distribution
Dental follicle cells and adipose tissue-derived stem cells
Species:  Human
Technique:  RT-PCR
References:  39
Spleen and isolated T- and B-lymphocytes.
Species:  Human
Technique:  RT-PCR.
References:  33
Heart, placenta, smooth muscle >> spleen, lymph node, thymus.
Species:  Human
Technique:  Northern blotting.
References:  27
Platelets
Species:  Human
Technique:  Western blotting
References:  3
Glial cells mainly in white matter, less abundant in grey matter.
Species:  Human
Technique:  Immunohistochemistry.
References:  29
HL-60 cells differentiated with DMSO (not expressed in wild-type HL-60 cells)
Species:  Human
Technique:  RT-PCR
References:  12
Placenta, adipose tissue, intestine > stomach, skeletal muscle > spleen, lung, heart > peripheral blood mononuclear cells, pituitary, various brain regions >> kidney, liver, prostate, pancreas, bone marrow.
Species:  Human
Technique:  RT-PCR.
References:  8
Neurons from dorsal root ganglia
Species:  Mouse
Technique:  RT-PCR
References:  28
Spleen, thymus > brain, heart, lung.
Species:  Mouse
Technique:  RT-PCR.
References:  11
Spinal microglia
Species:  Rat
Technique:  RT-PCR
References:  25
Forestomach>>distal stomach, rectum, colon, duodenum, jeunum, ileum, vagus nerve
Species:  Rat
Technique:  Real-time PCR
References:  3
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Rho activation assay
Species:  Human
Tissue:  Neutrophils and HL-60 cells
Response measured:  Activation of Rho GTPases
References:  35
Measurement of Ca2+ levels in monocyte-derived dendritic cells (MDDCs).
Species:  Human
Tissue:  MDDCs.
Response measured:  Ca2+ mobilisation.
References:  36
Measurement of Ca2+ levels in HEK 293 cells transfected with the P2Y14 recetor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Ca2+ mobilisation.
References:  29
Measurement of Ca2+ levels in epithelial cell lines A549 and BEAS-2B endogenously expressing the P2Y14 receptor.
Species:  Human
Tissue:  A549 and BEAS-2B cells.
Response measured:  Ca2+ mobilisation.
References:  30
Measurement of interleukin-8 (IL-8) secretion in epithelial cell lines A549 and BEAS-2B endogenously expressing the P2Y14 receptor.
Species:  Human
Tissue:  A549 and BEAS-2B cells.
Response measured:  Increase in IL-8 secretion.
References:  30
Measurement of cAMP levels in spleen-derived T-lymphocyte cells endogenously expressing the P2Y14 receptor.
Species:  Human
Tissue:  T-lymphocytes.
Response measured:  Small yet significant inhibition of cAMP accumulation.
References:  33
Measurement of cAMP levels in C6 cells
Species:  Rat
Tissue:  C6 glioma cells
Response measured:  inhibition of cAMP (abolished by PTX)
References:  26
Measurement of cAMP levels in neutrophils
Species:  Human
Tissue:  neutrophils
Response measured:  Inhibition of cAMP mediated by UDP-glucose stimulation, but not by UDP-galactose or UDP glucuronic acid. UDP N-acethyl-glucosamine produced a small but significant inhibition of cAMP
References:  34
MAP kinase activation assay
Species:  Human
Tissue:  DMSO differentiated HL-60 cells
Response measured:  Activation of ERK 1/2
References:  12
Intracellular calcium mobilization
Species:  Rat
Tissue:  RBL-2H3 mast cells
Response measured:  Calcium transients induced by UDP-glucose and MRS2690
References:  15
MAP kinase activation assay
Species:  Rat
Tissue:  RBL-2H3 mast cells
Response measured:  Activation of ERK1/2, JNK and P38 MAP kinases
References:  15
FLIPR and cellular impedance functional assays
Species:  Human
Tissue:  HEK293 cells
Response measured:  UMP and UDP selectively activate HEK cells coexpressing P2Y14 and Gqi5
References:  19
Physiological Functions
Chemotaxis of neutrophils
Species:  Human
Tissue:  Neutrophils
References:  35
Chemotaxis.
Species:  Human
Tissue:  Bone marrow stoma cells.
References:  27
Contractile effect on isolated forestomach
Species:  Rat
Tissue:  forestomach
References:  3
Role in neuroimmune function
Species:  Human
Tissue:  Glial cells
References:  29
Role in dendritic cells activation
Species:  Human
Tissue:  immunocytes
References:  36
Increase in mast cells degranulation
Species:  Rat
Tissue:  RBL-2H3 mast cells
References:  15
Inhibition of CFA induced hyperalgesia
Species:  Mouse
Tissue:  Peripheral neurous system
References:  28
Regulation of mesenchymal differentiation
Species:  Human
Tissue:  Adipose tissue-derived mesenchymal stem cells
References:  39
Physiological Consequences of Altering Gene Expression
In knockout mice there are no differences in terms of gastric emptying compared to wild-type
Species:  Rat
Tissue: 
Technique:  Gene targeting in embryonic stem cells
References:  3
Reduction of neuropathic pain. Inhibiting P2Y14 expression reverts mechanical allodynia induced after peripheral nerve injury
Species:  Rat
Tissue:  Peripheral nerves
Technique:  Antisense LNA
References:  25
P2Y14 knockout mice are protected from high-fat diet induced insulin resistance, show an improved insulin sensitivity, and a reduced hepatic steatosis
Species:  Mouse
Tissue:  Liver
Technique:  Gene knockouts
References:  37
P2Y14 ablation results in a reduced chemotaxis and number of macrophaes in the liver
Species:  Mouse
Tissue:  Macrophages
Technique:  Gene knockouts
References:  37
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
P2ry14tm1Gbtm P2ry14tm1Gbtm/P2ry14tm1Gbtm
B6.129P2-P2ry14
MGI:2155705  MP:0002106 abnormal muscle physiology PMID: 19164486 
General Comments
P2Y14 is selectively activated by sugar nucleotides. Only recently UDP has been demonstrated to act as an agonist at this receptor [6]. The different transcript variants for P2Y14 found in human and mouse encode for the same receptor protein.

References

Show »

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA et al.. (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev., 58 (3): 281-341. [PMID:16968944]

2. Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, Harden TK. (2013) A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose-Stimulated Chemotaxis of Human Neutrophils. Mol. Pharmacol., 84 (1): 41-9. [PMID:23592514]

3. Bassil AK, Bourdu S, Townson KA, Wheeldon A, Jarvie EM, Zebda N, Abuin A, Grau E, Livi GP, Punter L, Latcham J, Grimes AM, Hurp DP, Downham KM, Sanger GJ, Winchester WJ, Morrison AD, Moore GB. (2009) UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms. Am J Physiol Gastrointest Liver Physiol, 296: G923-G930. [PMID:19164486]

4. Bianco F, Fumagalli M, Pravettoni E, D'Ambrosi N, Volonté C, Matteoli M, Abbracchio MP, Verderio C. (2005) Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res Brain Res Rev, 48: 144-156. [PMID:15850653]

5. Burnstock G. (2017) Purinergic Signalling: Therapeutic Developments. Front Pharmacol, 8: 661. [PMID:28993732]

6. Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, Jacobson KA, Lazarowski ER, Harden TK. (2009) Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol. Pharmacol., 76 (6): 1341-8. [PMID:19759354]

7. Cekic C, Linden J. (2016) Purinergic regulation of the immune system. Nat. Rev. Immunol., 16 (3): 177-92. [PMID:26922909]

8. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson S, Livi GP. (2000) A G protein-coupled receptor for UDP-glucose. J Biol Chem, 275: 10767-10771. [PMID:10753868]

9. Das A, Ko H, Burianek LE, Barrett MO, Harden TK, Jacobson KA. (2010) Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J. Med. Chem., 53 (1): 471-80. [PMID:19902968]

10. Das A, Zhou Y, Ivanov AA, Carter RL, Harden TK, Jacobson KA. (2009) Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. Bioconjug. Chem., 20 (8): 1650-9. [PMID:19572637]

11. Freeman K, Tsui P, Moore D, Emson PC, Vawter L, Naheed S, Lane P, Bawagan H, Herrity N, Murphy K, Sarau HM, Ames RS, Wilson S, Livi GP, Chambers JK. (2001) Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. Genomics, 78: 124-128. [PMID:11735218]

12. Fricks IP, Carter RL, Lazarowski ER, Harden TK. (2009) Gi-dependent cell signaling responses of the human P2Y14-receptor in model cell systems. J Pharmacol Exp Ther,: -. [PMID:19339661]

13. Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, Harden TK. (2008) UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther, 325: 588-594. [PMID:18252808]

14. Fumagalli M, Brambilla R, D'Ambrosi N, Volonté C, Matteoli M, Verderio C, Abbracchio MP. (2003) Nucleotide-mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors. Glia, 43: 218-203. [PMID:12898701]

15. Gao ZG, Ding Y, Jacobson KA. (2010) UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem. Pharmacol., 79 (6): 873-9. [PMID:19896471]

16. Gao ZG, Wei Q, Jayasekara MP, Jacobson KA. (2013) The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal., 9 (1): 31-40. [PMID:22825617]

17. Gauthier JY, Belley M, Deschênes D, Fournier JF, Gagné S, Gareau Y, Hamel M, Hénault M, Hyjazie H, Kargman S et al.. (2011) The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14. Bioorg. Med. Chem. Lett., 21 (10): 2836-9. [PMID:21507640]

18. Guay D, Beaulieu C, Belley M, Crane SN, DeLuca J, Gareau Y, Hamel M, Henault M, Hyjazie H, Kargman S et al.. (2011) Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists. Bioorg. Med. Chem. Lett., 21 (10): 2832-5. [PMID:21507642]

19. Hamel M, Henault M, Hyjazie H, Morin N, Bayly C, Skorey K, Therien AG, Mancini J, Brideau C, Kargman S. (2011) Discovery of novel P2Y14 agonist and antagonist using conventional and nonconventional methods. J Biomol Screen, 16 (9): 1098-105. [PMID:21821827]

20. Ivanov AA, Fricks I, Kendall Harden T, Jacobson KA. (2007) Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. Bioorg Med Chem Lett, 17: 761-766. [PMID:17088057]

21. Jacobson KA, Deflorian F, Mishra S, Costanzi S. (2011) Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal., 7 (3): 305-24. [PMID:21484092]

22. Kiselev E, Balasubramanian R, Uliassi E, Brown KA, Trujillo K, Katritch V, Hammes E, Stevens RC, Harden TK, Jacobson KA. (2015) Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor. Bioorg. Med. Chem. Lett., 25 (21): 4733-9. [PMID:26303895]

23. Kiselev E, Barrett MO, Katritch V, Paoletta S, Weitzer CD, Brown KA, Hammes E, Yin AL, Zhao Q, Stevens RC et al.. (2014) Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes. ACS Chem. Biol., 9 (12): 2833-42. [PMID:25299434]

24. Ko H, Fricks I, Ivanov AA, Harden TK, Jacobson KA. (2007) Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem, 50: 2030-2039. [PMID:17407275]

25. Kobayashi K, Yamanaka H, Yanamoto F, Okubo M, Noguchi K. (2012) Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. Glia, 60 (10): 1529-39. [PMID:22736439]

26. Krzeminski P, Pomorski P, Baranska J. (2008) The P2Y14 receptor activity in glioma C6 cells. Eur J Pharmacol, 594: 49-54. [PMID:18638471]

27. Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber DA, Luster AD, Scadden DT. (2003) P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev, 17: 1592-1604. [PMID:12842911]

28. Malin SA, Molliver DC. (2010) Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol Pain, 6: 21. [PMID:20398327]

29. Moore DJ, Murdock PR, Watson JM, Faull RL, Waldvogel HJ, Szekeres PG, Wilson S, Freeman KB, Emson PC. (2003) GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res Mol Brain Res, 118: 10-23. [PMID:14559350]

30. Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow Jr JC, Luttmann W, Norgauer J, Di Virgilio F, Idzko M. (2005) The P2Y14 Receptor of Airway Epithelial Cells: Coupling to Intracellular Ca2+ and IL-8 Secretion. Am J Respir Cell Mol Biol,: -. [PMID:16109883]

31. Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S. (1994) Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res, 1: 27-35. [PMID:7584026]

32. Robichaud J, Fournier JF, Gagné S, Gauthier JY, Hamel M, Han Y, Hénault M, Kargman S, Levesque JF, Mamane Y et al.. (2011) Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14). Bioorg. Med. Chem. Lett., 21 (14): 4366-8. [PMID:21689930]

33. Scrivens M, Dickenson JM. (2005) Functional expression of the P2Y(14) receptor in murine T-lymphocytes. Br J Pharmacol, 146: 435-444. [PMID:15997228]

34. Scrivens M, Dickenson JM. (2006) Functional expression of the P2Y14 receptor in human neutrophils. Eur J Pharmacol, 543: 166-173. [PMID:16820147]

35. Sesma JI, Kreda SM, Steinckwich-Besancon N, Dang H, García-Mata R, Harden TK, Lazarowski ER. (2012) The UDP-sugar-sensing P2Y(14) receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils. Am. J. Physiol., Cell Physiol., 303 (5): C490-8. [PMID:22673622]

36. Skelton L, Cooper M, Murphy M, Platt A. (2003) Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. J Immunol, 171: 1941-1949. [PMID:12902497]

37. Xu J, Morinaga H, Oh D, Li P, Chen A, Talukdar S, Mamane Y, Mancini JA, Nawrocki AR, Lazarowski E et al.. (2012) GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity. J. Immunol., 189 (4): 1992-9. [PMID:22778393]

38. Yu J, Ciancetta A, Dudas S, Duca S, Lottermoser J, Jacobson KA. (2018) Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor. Journal of Medicinal Chemistry, 61 (11): 4860-4882 Articles ASAP. DOI: 10.1021/acs.jmedchem.8b00168

39. Zippel N, Limbach CA, Ratajski N, Urban C, Luparello C, Pansky A, Kassack MU, Tobiasch E. (2012) Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev., 21 (6): 884-900. [PMID:21740266]

Contributors

Show »

How to cite this page

Maria-Pia Abbracchio, Jean-Marie Boeynaems, José L. Boyer, Geoffrey Burnstock, Stefania Ceruti, Marta Fumagalli, Christian Gachet, Rebecca Hills, Robert G. Humphries, Kenneth A. Jacobson, Charles Kennedy, Brian F. King, Davide Lecca, Maria Teresa Miras-Portugal, Gary A. Weisman.
P2Y receptors: P2Y14 receptor. Last modified on 22/06/2018. Accessed on 13/11/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=330.